Work

Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4544

Authors: Charlene Mantia, Opeyemi Jegede, Meredith M. Regan, Michael B. Atkins, David F. McDermott

Institutions: Dana-Farber Cancer Institute, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286294224

Cites:

Cited by: 2

Related to: 10